We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+78.01%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.2B
AUM Growth
-$344M
Cap. Flow
-$568M
Cap. Flow %
-47.21%
Top 10 Hldgs %
59.33%
Holding
55
New
8
Increased
5
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$34M
2
AVBP icon
ArriVent BioPharma
AVBP
+$20M
3
MANE
Veradermics Inc
MANE
+$15.1M
4
FTH
Faeth Therapeutics
FTH
+$14.4M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$9.12M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$211M
2
TERN
Terns Pharmaceuticals
TERN
+$165M
3
COGT icon
Cogent Biosciences
COGT
+$73M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$57.8M
5
ZBIO
Zenas BioPharma
ZBIO
+$31M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ERAS icon
1
Erasca
ERAS
$6.28B
$197M 16.34%
12,151,480
+2,878,052
+31% +$34M
PRAX icon
2
Praxis Precision Medicines
PRAX
$8.18B
$109M 9.08%
338,895
+10,000
+3% +$3.09M
TERN
3
DELISTED
Terns Pharmaceuticals
TERN
$70.4M 5.85%
1,334,418
-4,012,510
-75% -$165M
TRVI icon
4
Trevi Therapeutics
TRVI
$2.59B
$60.8M 5.05%
5,094,668
– –
DBVT
5
DBV Technologies
DBVT
$798M
$55.7M 4.63%
2,667,569
+205,943
+8% +$4.3M
CMPX icon
6
Compass Therapeutics
CMPX
$364M
$50.5M 4.2%
9,545,466
– –
TNGX icon
7
Tango Therapeutics
TNGX
$4.27B
$45.1M 3.75%
2,154,780
– –
SABS icon
8
SAB Biotherapeutics
SABS
$262M
$43.7M 3.64%
11,420,000
– –
CRVS icon
9
Corvus Pharmaceuticals
CRVS
$1.09B
$41M 3.41%
2,805,816
+571,250
+26% +$9.12M
DRUG
10
Bright Minds Biosciences
DRUG
$702M
$40.7M 3.38%
557,172
+55,555
+11% +$4.47M
SVA
11
DELISTED
Sinovac Biotech, Ltd
SVA
$38.2M 3.17%
5,903,000
– –
DNTH icon
12
Dianthus Therapeutics
DNTH
$5.6B
$29.7M 2.47%
353,998
– –
DYN icon
13
Dyne Therapeutics
DYN
$4.24B
$28.2M 2.35%
1,557,466
-1,057,494
-40% -$18.2M
ABVX
14
Abivax
ABVX
$10.9B
$26.7M 2.22%
239,539
-119,766
-33% -$14.2M
NERV icon
15
Minerva Neurosciences
NERV
$194M
$26M 2.17%
4,322,747
– –
ACRS icon
16
Aclaris Therapeutics
ACRS
$733M
$25M 2.08%
6,666,666
-2,222,222
-25% -$7.5M
ORIC icon
17
Oric Pharmaceuticals
ORIC
$1.22B
$23.4M 1.95%
1,848,786
-269,598
-13% -$3.06M
ANRO icon
18
Alto Neuroscience
ANRO
$1.05B
$23.3M 1.94%
1,035,551
– –
FTH
19
Faeth Therapeutics
FTH
$735M
$22.8M 1.89%
+722,020
New +$14.4M
AVBP icon
20
ArriVent BioPharma
AVBP
$1.38B
$20.4M 1.7%
+885,916
New +$20M
LBRX
21
LB Pharmaceuticals
LBRX
$1.01B
$19.7M 1.64%
800,000
– –
MANE
22
Veradermics Inc
MANE
$4.69B
$18.9M 1.57%
+300,000
New +$15.1M
CAMP icon
23
CAMP4 Therapeutics
CAMP
$176M
$18.7M 1.56%
4,246,568
– –
MLTX icon
24
MoonLake Immunotherapeutics
MLTX
$1.61B
$18.6M 1.55%
1,000,000
– –
DSGN icon
25
Design Therapeutics
DSGN
$727M
$17.2M 1.43%
1,612,903
– –
1
2 3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
WC
Whitney & Co Rochester, New York $1.2B AUM 24.16% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Vivo Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Vivo Capital held 55 positions worth $1.2B, down 22% from $1.55B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Vivo Capital withdrew a net $568M in Q1 2026, closing 9 positions and reducing 9 holdings. Its most notable exit was Cidara Therapeutics, an estimated $211M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Vivo Capital opened a new position in ArriVent BioPharma worth $20.4M.

  • Vivo Capital's largest Q1 2026 buy was ArriVent BioPharma: 885,916 shares worth $20.4M.
  • Vivo Capital added most to Erasca in Q1 2026, an estimated $34M increase.
  • Vivo Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $165M.
  • Vivo Capital fully exited Cidara Therapeutics in Q1 2026, selling an estimated $211M.
  • Vivo Capital's ten largest holdings make up 59% of its $1.2B portfolio in Q1 2026.
  • Vivo Capital opened 8 new positions and closed 9 in Q1 2026.
  • Vivo Capital's portfolio value fell 22% quarter-over-quarter to $1.2B.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.